Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
Phase 2 Completed
46 enrolled 15 charts
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Phase 1/2 Completed
332 enrolled 44 charts
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer
Phase 1 Completed
46 enrolled
CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
Phase 1/2 Completed
49 enrolled
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Phase 1 Completed
9 enrolled
Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer
Phase 2 Completed
34 enrolled 10 charts
NEOPAN
Phase 3 Completed
171 enrolled
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
Phase 1 Completed
139 enrolled
Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
Phase 1 Completed
46 enrolled
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
Phase 2 Completed
11 enrolled 12 charts
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
Phase 1/2 Completed
213 enrolled 42 charts
Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
Phase 2 Completed
29 enrolled 8 charts
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Phase 2 Completed
229 enrolled 14 charts
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
Phase 1 Completed
50 enrolled
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
Phase 1 Completed
15 enrolled
FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Phase 2 Completed
28 enrolled 10 charts
mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer
Phase 2 Completed
40 enrolled
Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer
Phase 3 Completed
27 enrolled 15 charts
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Phase 2 Completed
56 enrolled 19 charts
Post Marketing Surveillance Study for ONIVYDE® in South Korea
Completed
94 enrolled
Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer
Phase 2 Completed
50 enrolled 13 charts
FOLFOX-D
Phase 2 Completed
44 enrolled 18 charts
Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours
Phase 2 Completed
56 enrolled
Sequoia
Phase 3 Completed
567 enrolled 17 charts
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Phase 1 Completed
236 enrolled 21 charts
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
Phase 1 Completed
79 enrolled
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
Phase 1 Completed
66 enrolled
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
Phase 1 Completed
15 enrolled
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
Phase 1 Completed
7 enrolled
BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer
Phase 1 Completed
17 enrolled
Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets
Phase 2 Completed
9 enrolled 8 charts
Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas
Phase 3 Completed
100 enrolled
FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Phase 1 Completed
44 enrolled
NAPOLI-1
Phase 3 Completed
417 enrolled 20 charts
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
Phase 1 Completed
180 enrolled
PROSPECT
Phase 2/3 Completed
312 enrolled
Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer
Phase 3 Completed
108 enrolled
Combination Chemotherapy in Treating Patients With Advanced Cancer of the Pancreas
Phase 2 Completed
21 enrolled
Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Phase 3 Completed
202 enrolled
Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer
Phase 3 Completed
1,030 enrolled
S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer
Phase 2 Completed
54 enrolled
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
Phase 1 Completed
108 enrolled
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
Phase 1 Completed
Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas
Phase 1 Completed
25 enrolled
GFF
Phase 2 Completed
78 enrolled